The world’s first Ebola vaccine is finally approved. A critical move that opens the door for its use in countries at high risk for the infectious disease.
The European Commission granted marketing authorization to Merck’s vaccine, known as Ervebo, on Monday.
Less than a month after the European Medicines Agency recommended it be licensed. It is currently being used in the Democratic Republic of the Congo. Under a “compassionate use” or research protocol similar to a clinical trial.
“The European Commission’s marketing authorization of Ervebo. Is the result of an unprecedented collaboration for which the entire world should be proud.” Ken Frazier. Merck’s chairman and chief executive officer, said in a statement.
Frazier said Merck will also work with the World Health Organization on vaccine prequalification, a process in which the global health agency assesses vaccines. And other medical processes in order to assure member countries that they are safe and effective.
Developing countries often use WHO prequalification as guidance. When they make their own decisions about whether to license a product.